Concepedia

Haby Henary

HH

22

Publications

6.3K

Citations

16

H-Index

2008

Active since

Affiliations

Amgen (United States)(Current)

The University of Texas MD Anderson Cancer Center

Peter MacCallum Cancer Centre

Memorial Sloan Kettering Cancer Center

Indiana University – Purdue University Indianapolis

Haby Henary is an author at Amgen (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

2008–2022

22

Publications

22

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.2K citations

, , +5

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule <i>KRAS<sup>G12C</sup></i> inhibitor, in advanced solid tumors.

Marwan Fakih, Bert H. O’Neil, Timothy Price et al. · Journal of Clinical Oncology · 2019 · 172 citations

, , +18

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

William Larry Gluck, Mrinal M. Gounder, Richard C. Frank et al. · Investigational New Drugs · 2019 · 120 citations · Full text

Rows per page

1–5 of 22